Skip to main content

In honor of World Cancer Day on February 4, members of the Oncology Data Advisor Fellows Forum and Editorial Board joined forces for a thought-provoking discussion about improving cancer care on a global scale, including treatment access, molecular t...
Recently, the FDA granted approval to capivasertib in combination with fulvestrant for patients with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative locally advanced or metastatic breast cancer with one or more PIK...
At the recent San Antonio Breast Cancer Symposium (SABCS), numerous updates were presented which have the potential to improve treatment outcomes for patients with breast cancer. After returning from the meeting, Dr. Jason Mouabbi, Assistant Professo...
Oncology Data Advisor® · Capivasertib for PIK3CA/AKT1/PTEN–Altered Breast Cancer With Jason Mouabbi, MD, and Carlos Doti, MD Recently, the FDA granted approval to capivasertib in combination with fulvestrant for patients with hormone...
Oncology Data Advisor® · Highlights From the 2023 San Antonio Breast Cancer Symposium With Jason Mouabbi, MD At the recent San Antonio Breast Cancer Symposium (SABCS), numerous updates were presented which have the potential to improve tre...
Oncology Data Advisor® · Real-World Use Patterns, Effectiveness, & Tolerability of Sacituzumab Govitecan for TNBC At this year's European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, Dr. Kevin Kalinsky, Director of th...
The FDA has approved capivasertib (Truqap™, AstraZeneca Pharmaceuticals) in combination with fulvestrant for adult patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative locally advanced or metastatic b...
In 2006, after being diagnosed with breast cancer at the age of 32, Maimah Karmo decided to dedicate herself to empowering women with breast cancer to serve as advocates for themselves, resulting in the creation of Tigerlily Foundation. In this inter...
Eun-Ok Im, PhD, MPH, RN, CNS, FAAN, was recently named as the recipient of the 2023 Oncology Nursing Society (ONS) Distinguished Nurse Researcher Award. At this past ONS Congress, Dr. Im gave a presentation on her pioneering use of technology and Int...